Skip to main content

Table 1 Incidence Rate Ratio for weekly confirmed cases during the pandemic period (week 12-39)a

From: Gender disparities in access to care for time-sensitive conditions during COVID-19 pandemic in Chile

 

Both sexes

Men

Women

Level effect

Slope effect

Level effect

Slope effect

Level effect

Slope effect

All cardiovascular diseases

0.586 (0.564–0.609)

1.009 (1.007–1.011)

0.621 (0.593–0.65)

1.008 (1.005–1.01)

0.553 (0.527–0.579)

1.01 (1.008–1.012)

Stroke (includes transient ischemic attack)

0.653 (0.617–0.691)

1.008 (1.006–1.011)

0.697 0.649–0.75)

1.008 (1.005–1.012)

0.613 (0.571–0.658)

1.008 (1.005–1.012)

Myocardial infarction

0.563 (0.539–0.589)

1.009 (1.007–1.011)

0.595 (0.566–0.627)

1.007 (1.005–1.01)

0.532 (0.502–0.564)

1.011 (1.008–1.014)

All cancer

0.323 (0.291–0.359)

1.022 (1.016–1.028)

0.364 (0.315–0.42)

1.024 (1.017–1.031)

0.312 (0.279–0.35)

1.021 (1.015–1.028)

All cancer (excluding sex specific cancer)

0.293 (0.258–0.334)

1.028 (1.021–1.035)

0.351 (0.302–0.408)

1.025 (1.017–1.033)

0.254 (0.218–0.296)

1.03 (1.022–1.038)

Gastric cancer

0.306 (0.253–0.371)

1.022 (1.011–1.032)

0.338 (0.265–0.431)

1.021 (1.008–1.035)

0.228 (0.231–0.36)

1.021 (1.009–1.033)

Colorectal cancer

0.229 (0.199–0.265)

1.036 (1.028–1.043)

0.295 (0.248–0.35)

1.032 (1.023–1.041)

0.19 (0.159–0.228)

1.038 (1.029–1.048)

Lymphoma

0.569 (0.467–0.693)

1.017 (1.007–1.028)

0.643 (0.49–0.844)

1.009 (0.996–1.022)

0.497 (0.378–0.655)

1.025 (1.01–1.039)

Leukaemia

0.388 (0.286–0.526)

1.031 (1.015–1.047)

0.383 (0.251–0.586)

1.034 (1.011–1.058)

0.392 (0.259–0.594)

1.027 (1.006–1.05)

Cervical cancer (includes dysplasia)

0.335 (0.287–0.392)

1.007 (0.998–1.016)

Breast cancer

0.336 (0.293–0.385)

1.028 (1.021–1.036)

Testicular cancer

0.469 (0.339–0.649)

1.013 (0.997–1.029)

  1. aInterrupted time series analysis by sex adjusted by age, population size, and seasonality (week and year). The model includes level and slope effect terms. Complete models are available in Supplemental material (Table S3-S5)